Report : South & Central America Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)

At 6.8% CAGR, the South & Central America Influenza Vaccines Market is speculated to be worth US$ 736.35 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America influenza vaccines market was valued at US$ 497.54 million in 2022 and is expected to reach US$ 736.35 million by 2028, registering an annual growth rate of 6.8% from 2022 to 2028. The strong pipeline candidates for influenza vaccines   and emerging economies and are the critical factors attributed to the market expansion.

Leading players in the influenza vaccines market have multiple projects on drug delivery and biological pipelines based on proprietary technology. The most advanced candidate population in drug delivery completed 2 Phase I studies. The pipeline also includes a large number of compounds that have completed preclinical evaluation. Pipeline candidates are focused on unlocking the science of the immune system, human genetics, and cutting-edge technologies to develop innovative vaccines. Companies are investing in scientific and technical excellence to develop and introduce new vaccines and specific drugs against infectious diseases, including influenza. Vaccines and viral therapeutic candidates in the pipeline are capable of rapidly and specifically responding to the most pressing health threats.

On the contrary, high cost of vaccine development hurdles the growth of South & Central America influenza vaccines market.

  • Based on vaccine type, the South & Central America influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment held 88.0% market share in 2022, amassing US$ 438.02 million. It is projected to garner US$ 658.30 million by 2028 to expand at 7.0% CAGR during 2022–2028.
  • Based on virus type, the South & Central America influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held 96.1% market share in 2022, amassing US$ 478.37 million. It is projected to garner US$ 714.34 million by 2028 to expand at 6.9% CAGR during 2022–2028.
  • Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held 78.4% market share in 2022, amassing US$   389.85 million. It is projected to garner US$ 568.12 million by 2028 to expand at 6.5% CAGR during 2022–2028.
  • Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held 72.2% market share in 2022, amassing US$ 359.45 million. It is projected to garner US$ 542.54 million by 2028 to expand at 7.1% CAGR during 2022–2028.
  • Based on country, the South & Central America influenza vaccines market is categorized into Brazil, Argentina, and the rest of South & Central America. Our regional analysis states that Brazil captured 68.6% market share in 2022. It was assessed at US$ 341.29 million in 2022 and is likely to hit US$ 512.35 million by 2028, exhibiting a CAGR of 7.0% during the forecast period.

Key players dominating the South & Central America influenza vaccines market are AstraZeneca; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure